Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

First-in-Class Targeted Protein Degrader of MLLT1/3 for the Treatment of Advanced AML and ALL Including Menin Inhibitor Resistant / Refractory Disease

John Pollard, Graham Craggs, Gillian Farnie, Matthew Fawkes, Fenella Gross, Joe Harman, Marta Llorca-Cardenosa, Sarah Major, Alison Maloney, Thomas A Milne, Iain Simpson

Blood (2024) 144 (Supplement 1): 2772.

https://doi.org/10.1182/blood-2024-210052

Published: 2024

Journal Articles

Novel Inhibitors of MLLT1/3, a Critical Component of the Super-Elongation Complex (SEC), Target a Range of Molecularly Defined Acute Leukemias, with a Differential Profile to Menin Inhibition

John Pollard, Graham Craggs, Gillian Farnie, Matthew Fawkes, Oleg Fedorov, Charline Giroud, Fenella Gross, Joe Harman, Alison Maloney, Thomas Arthur Milne, Iain Simpson

Blood (2023) 142 (Supplement 1): 2789.

https://doi.org/10.1182/blood-2023-186638

Published: 2023

Journal Articles

Inhibition of ATR in Combination with Nucleoside Analogues Eradicates Acute Myeloid Leukaemia in an Orthotopic Murine Xenograft Model

Sarah E Fordham, PhD, Helen J Blair, PhD, Claire J Elstob, PhD, Deepali Pal, PhD, Nicola Curtin, PhD, Paul Milne, PhD, Matthew Collin, MD PhD, Graham H Jackson, MD MBBS, Helen J Marr, MD PhD, Olaf Heidenreich, PhD, Ruth Plummer, John Pollard, PhD, Tobias F. Menne, MD PhD FRCPath, Gail L Jones, MD BMBS, James M Allan, DPhil

Blood (2016) 128 (22): 4031.

https://doi.org/10.1182/blood.V128.22.4031.4031

Published: 2016

Journal Articles

Combined Effects of a Pan-Aurora Kinase Inhibitor MK-0457 and Dasatinib Against T315I Mutant Form of BCR-ABL: In Vitro and In Vivo Studies.

Tetsuzo Tauchi, MD, Daigo Akahane, MD, Kousuke Nunoda, MD, Seiichi Okabe, MD, John Pollard, PhD, Kazuma Ohyashiki, MD

Blood (2007) 110 (11): 805.

https://doi.org/10.1182/blood.V110.11.805.805

Published: 2007

Journal Articles

Anti-Myeloma Activity of the Small-Molecule Aurora Kinase Inhibitor VE465.

Joseph M. Negri, Douglas W. McMillin, Nicholas Mitsiades, Teru Hideshima, Dharminder Chauhan, Yu-Tzu Tai, Xavier Leleu, Nikhil C. Munshi, Paul G. Richardson, Carolyn A. Buser-Doepner, John Pollard, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2006) 108 (11): 3468.

https://doi.org/10.1182/blood.V108.11.3468.3468

Published: 2006

Journal Articles

MK-0457, a Novel Multikinase Inhibitor, Inhibits BCR-ABL Activity in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Mutation.

Donald A. Bergstrom, MD, PhD, Jason B. Clark, PhD, Alan Xiao, PhD, Matthew Griffiths, PhD, Susannah Falcon, PhD, John Pollard, PhD, Steven J. Freedman, MD,PhD, Francis Giles, MD

Blood (2006) 108 (11): 637.

https://doi.org/10.1182/blood.V108.11.637.637

Published: 2006

NARROW

First-in-Class Targeted Protein Degrader of MLLT1/3 for the Treatment of Advanced AML and ALL Including Menin Inhibitor Resistant / Refractory Disease

Novel Inhibitors of MLLT1/3, a Critical Component of the Super-Elongation Complex (SEC), Target a Range of Molecularly Defined Acute Leukemias, with a Differential Profile to Menin Inhibition

Inhibition of ATR in Combination with Nucleoside Analogues Eradicates Acute Myeloid Leukaemia in an Orthotopic Murine Xenograft Model

Combined Effects of a Pan-Aurora Kinase Inhibitor MK-0457 and Dasatinib Against T315I Mutant Form of BCR-ABL: In Vitro and In Vivo Studies.

Anti-Myeloma Activity of the Small-Molecule Aurora Kinase Inhibitor VE465.

MK-0457, a Novel Multikinase Inhibitor, Inhibits BCR-ABL Activity in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Mutation.

Email alerts

ASH Publications

American Society of Hematology

First-in-Class Targeted Protein Degrader of MLLT1/3 for the Treatment of Advanced AML and ALL Including Menin Inhibitor Resistant / Refractory Disease

Novel Inhibitors of MLLT1/3, a Critical Component of the Super-Elongation Complex (SEC), Target a Range of Molecularly Defined Acute Leukemias, with a Differential Profile to Menin Inhibition

Inhibition of ATR in Combination with Nucleoside Analogues Eradicates Acute Myeloid Leukaemia in an Orthotopic Murine Xenograft Model

Combined Effects of a Pan-Aurora Kinase Inhibitor MK-0457 and Dasatinib Against T315I Mutant Form of BCR-ABL: In Vitro and In Vivo Studies.

Anti-Myeloma Activity of the Small-Molecule Aurora Kinase Inhibitor VE465.

MK-0457, a Novel Multikinase Inhibitor, Inhibits BCR-ABL Activity in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Mutation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only